HSE approves use of €430,000 drug for two patients

The HSE has reached an agreement to provide the drug Soliris to sufferers of two rare diseases at an annual cost of €430,000 per patient.

Due to the cost of the drug, it will be administered to sufferers of Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Haemolytic Uraemic (aHUS) on the basis of clinical need.